Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Treatment.com International ( (TSE:TRUE) ) has shared an update.
Treatment.com AI Inc. has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology Ltd to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and the Far East. The partnership aims to combine Aiyibotong’s CDSS with Treatment’s Global Library of Medicine to enhance patient support and increase market share. This collaboration aligns with the growing investment in digital health in China, expected to reach $45 billion in 2025, and the CDSS market projected to double by 2030. The agreement includes co-marketing efforts and the development of an AI-based CDSS for the global market, leveraging both companies’ technologies and expertise.
More about Treatment.com International
Treatment.com AI Inc. is a company focused on providing enhanced clinical decision support for healthcare professionals and patients using innovative technologies such as artificial intelligence and machine learning. It collaborates with Aiyibotong, a China-based healthcare information technology company that offers clinical decision support solutions for medical professionals in hospitals and clinics.
YTD Price Performance: -6.06%
Average Trading Volume: 10,013
Technical Sentiment Signal: Buy
Current Market Cap: $15.15M
For a thorough assessment of TRUE stock, go to TipRanks’ Stock Analysis page.